AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology

Written by Petra Hegmann on 27th May 2021. Posted in Client News.

• Previous
• Next